Indoco Remedies Ratios

Indoco Remedies Ltd Ratios

The Indoco Remedies Ltd Ratios page provides a complete fundamental analysis of Indoco Remedies Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Indoco Remedies Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Indoco Remedies Ltd (NSE: INDOCO, BSE: 532612) is currently trading at ₹192.20, with a market capitalization of ₹17.66B. As a major player in the Health technology sector and Pharmaceuticals: major industry, Indoco Remedies Ltd remains a key stock for fundamental analysis using Indoco Remedies Ltd Ratios.

Indoco Remedies Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Indoco Remedies Ltd P/E ratio currently stands at 0, making it one of the most tracked metrics in Indoco Remedies Ltd Ratios.

Historically, the Indoco Remedies Ltd P/E ratio has shown strong fluctuations:

• 2024: 0
• 2023: 30.78
• 2022: 21.11
• 2021: 22.42
• 2020: 28.57

The decline in Indoco Remedies Ltd P/E ratio suggests improving earnings relative to stock price.

Price to Book Ratio (P/B)

The Indoco Remedies Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 2.10.

Historical P/B trend:

• 2024: 2.10
• 2023: 2.73
• 2022: 2.92
• 2021: 3.84

Indoco Remedies Ltd shows reasonable valuation compared to its asset base.

Price to Sales Ratio (P/S)

The Indoco Remedies Ltd P/S ratio currently stands at 1.31, an important part of Indoco Remedies Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 1.31
• 2023: 1.69
• 2022: 1.83
• 2021: 2.31

A stable or declining Indoco Remedies Ltd P/S ratio indicates cautious market sentiment.

Indoco Remedies Ltd Price to Cash Flow Ratio (P/CF)

The Indoco Remedies Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 77.10.

Historical Indoco Remedies Ltd Price to Cash Flow Ratio:

• 2024: 77.10
• 2023: 24.96
• 2022: 19.75
• 2021: 22.68
• 2020: 44.51

The rising Indoco Remedies Ltd Price to Cash Flow Ratio indicates premium valuation based on cash flow.

Indoco Remedies Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Indoco Remedies Ltd EV currently stands at ₹31.24B, representing the total company valuation including debt.

Historical EV trend:

• 2024: 31.24B
• 2023: 36.72B
• 2022: 33.22B
• 2021: 37.07B

Indoco Remedies Ltd enterprise value consolidation suggests stable valuation.

EV/EBITDA Ratio

The Indoco Remedies Ltd EV/EBITDA ratio is currently 38.05, a key metric in Indoco Remedies Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 38.05
• 2023: 16.61
• 2022: 12.67
• 2021: 12.68

Higher Indoco Remedies Ltd EV/EBITDA suggests premium valuation.

Indoco Remedies Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Indoco Remedies Ltd D/E ratio is currently 0.97, reflecting leverage and financial stability.

Historical D/E:

• 2024: 0.97
• 2023: 0.61
• 2022: 0.32
• 2021: 0.28

Indoco Remedies Ltd maintains moderate leverage with manageable risk.

Return on Equity (ROE %)

The Indoco Remedies Ltd ROE currently stands at -6.92%, showing profitability and capital efficiency.

Historical ROE:

• 2024: -6.92
• 2023: 9.21
• 2022: 14.72
• 2021: 18.50

Declining ROE indicates pressure on profitability.

Indoco Remedies Ltd Ratios Analysis Summary

The Indoco Remedies Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Indoco Remedies Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Indoco Remedies Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.